On April 22, 2022 Alligator Bioscience will host a conference call (in English) for investors, analysts and media on Wednesday, April 27, 2022, at 15:30 CET (Press release, Alligator Bioscience, APR 22, 2022, View Source [SID1234612805]). Alligator will publish the company’s interim report on Wednesday, April 27, 2022, at 8:00 CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO, Søren Bregenholt and CFO, Marie Svensson will present the interim report for the period January – March 2022 Report followed by a Q&A session.

The conference call will be broadcast live on the web and can be accessed via the link: Alligator Bioscience , Audiocast with teleconference, Q1, 2022 | Financial Hearings

On April 22, 2022 Genoscience Pharma reported that it is enthusiastic, after having selected , about presenting the company during the Company Showcase Presentation Oncology session during Biotrinity on Tuesday morning 26th April (Press release, GenoScience, APR 22, 2022, View Source [SID1234612806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Several Investors and pharma companies will be present during this Business Convention.

Date: 26-27th April 2022

Location: London

On April 22, 2022 CEL-SCI Corporation (NYSE American: CVM) reported that two abstracts related to CEL-SCI’s pivotal Phase 3 head and neck cancer clinical trial were accepted at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting being held June 3-7, 2022 in Chicago, IL (Press release, Cel-Sci, APR 22, 2022, View Source [SID1234612875]). After a two-year hiatus, ASCO (Free ASCO Whitepaper) comes alive in June 2022 under the theme, "Advancing Equitable Cancer Care Through Innovation." ASCO (Free ASCO Whitepaper) is the largest cancer meeting in the world, bringing together thousands of cancer experts from academia, industry, patient advocacy and policy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About Multikine

Multikine* (Leukocyte Interleukin, Injection) is an investigational cancer immunotherapy that is known to contain a mixture of natural human proinflammatory cytokines, the body’s immune system regulators including interleukins, interferons, chemokines, and colony stimulating factors which are elements of the body’s natural mix of defenses against cancer and other diseases. A patented, mass-produced, off the shelf, non-autologous biological investigational product, Multikine is manufactured using a proprietary process following Current Good Manufacturing Practice (cGMP) at CEL-SCI’s manufacturing facility near Baltimore, Maryland.

About Head and Neck Cancer

Approximately 890,000 new cases of head and neck cancer are diagnosed each year globally, of which approximately 68,000 are in the U.S. and 150,000 in Europe.

On April 21, 2022 CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), reported preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed with GSK, combining two mRNAs encoding for the Beta and the Delta variant (Press release, GlaxoSmithKline, APR 21, 2022, View Source [SID1234612733]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model. Despite containing only half the dose per variant-mRNA, the combined Beta/Delta candidate elicited neutralizing antibody titers fully comparable to the monovalent candidates of the respective variant. During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals. High neutralizing antibody titers were accompanied by robust T cell responses. Notably, the bivalent Beta /Delta vaccine candidate induced two-fold higher virus neutralizing antibody titers against the Omicron variant than against the Delta variant in a rat model. This finding provides evidence for a potentially increased breadth of immune responses of the bivalent approach. The full manuscript of the preclinical data is available on the preprint server bioRxiv.

"Since the beginning of the pandemic, new COVID-19 variants have continued to evolve, each characterized by different virulence and transmissibility," said Dr. Igor Splawski, Chief Scientific Officer of CureVac. "New vaccine strategies, such as multivalent approaches, combining several variant-specific mRNAs within one vaccine, can be essential to take control over the COVID-19 virus dynamic and set new standards for broadly effective vaccines against other infectious diseases. Following our recent multivalent approach for influenza, we are now taking advantage of this advanced technology approach in our COVID-19 vaccine program.

Within the study, transgenic mice expressing the human ACE2 receptor were immunized on day 0 and day 28 with a 0.5 µg dose of the monovalent second-generation vaccine candidate against either the ancestral virus (CV2CoV), the Beta (CV2CoV.351) or the Delta (CV2CoV.617.2) variant, or with a 0.5 µg dose of the bivalent vaccine candidate combining the Beta and Delta variant (CV2CoV.351+ CV2CoV.617.2). Vaccinated animals were challenged on day 56 with either the Beta or the Delta virus variant. Vaccine induced T cells, including lung-resident memory CD8+ T cells, were characterized by flow cytometry. Additionally, the neutralizing capacity of the mono- and bivalent candidates was tested against multiple virus variants, including Omicron in serum samples of immunized Wistar rats.

On April 21, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported its participation in the annual meeting of the German Society for Nuclear Medicine from April 27-30, 2022 (Press release, ITM Isotopen Technologien Munchen, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612876]). The conference also represents the 60th anniversary congress of the society and will take place as a hybrid event online and in Leipzig. ITM will host a lunchtime symposium on April 28 on Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective and will also showcase its precision oncology product portfolio at a booth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of ITM’s symposium, Prof. Wolfgang Wadsak, Head of Medical Radiochemistry and Biomarker Development in the Clinical Department for Nuclear Medicine at the University Hospital Vienna , will talk about the production of radiopharmaceuticals for direct application in the field of cancer medicine in clinics and as an essential component and innovation driver in nuclear medicine to speak. Neil Quigley, Global Product Manager, ITM , will present the latest developments and potential indications in the field of targeted radionuclide therapy using the alpha emitter Actinium-225. This topic is supplemented by a lecture by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, on development opportunities for the innovative radioisotope actinium-225 and on the worldwide supply security of clinics with the established, high-purity medical radioisotope nca lutetium-177 (no-carrier-added). The symposium is part of the official conference program and will take place on April 28, 2022 from 12:30 pm to 1:30 pm in Hall 2 of the congress building.

"We are pleased to complement the scientific conference program with our symposium. The manufacturing of radiopharmaceuticals in clinics is an essential prerequisite to be able to offer cancer patients targeted radionuclide therapies, while the industry develops ready-to-use radiopharmaceuticals," says Steffen Schuster, CEO of ITM . "With our research and development of precision oncological diagnostics and therapeutics for various cancer indications as well as our current product portfolio of medical radioisotopes and radiolabeling equipment, we want to contribute to giving patients worldwide access to targeted cancer therapies that have the potential to improve treatment outcomes and quality of life."

At booth (#A6) in the conference’s industrial exhibition, ITM will present its proprietary portfolio of high-quality medical radioisotopes, as well as all the equipment needed for manufacturing and quality control of radiopharmaceuticals.

– end –

ITM’s research and development activities in the field of precision oncology

In addition to ITM’s central position in the development, production and distribution of medical radioisotopes and radiolabeling equipment, ITM is developing its own broad pipeline of diagnostic and therapeutic radiopharmaceuticals for various cancer indications. ITM’s lead candidate ITM-11 for the treatment of neuroendocrine tumors of gastroentero-pancreatic origin (GEP-NETs) is currently in two phase III studies, COMPETE and COMPOSE. ITM recently announced the successful completion of patient enrollment for the COMPETE trial evaluating ITM-11 for grade 1 and 2 GEP-NETs . In COMPOSE, ITM-11 will be studied for grade 2 and 3 GEP-NETs in order to evaluate ITM-11 for a broader GEP-NET indication.

Targeted radionuclide therapy

Targeted radionuclide therapy is a new form of cancer therapeutics that aim to irradiate the tumor directly while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are made by combining a therapeutic radioisotope with a targeting molecule (eg, peptide, antibody, small molecule) that can accurately recognize tumor cells and bind to tumor-specific features such as receptors on the surface of the tumor cells. The radioisotope accumulates at the tumor and decays, releasing a small amount of ionizing radiation capable of destroying tumor tissue. The high-precision localization enables targeted treatment with potentially minimal effects on the surrounding healthy tissue.